Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • adamwangwang47 adamwangwang47 Apr 30, 2013 4:14 PM Flag

    Lomitapide inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which is necessary for very low-density lipoprotein (VLDL) as

    fatty liver will show up after taking for 12-18 months

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • system_architect_enterprise system_architect_enterprise Apr 30, 2013 4:26 PM Flag

      Of course, if they don't take the drug, they will be dead, so I guess I'd take the drug and then deal with a fatty liver.

      • 1 Reply to system_architect_enterprise
      • you don't know what you are talking about:

        Heterozygous FH is a common genetic disorder, inherited in an autosomal dominant pattern, occurring in 1:500 people in most countries; Heterozygous FH is normally treated with statins, bile acid sequestrants or other hypolipidemic agents that lower cholesterol levels.

        Homozygous FH is much rarer, occurring in 1 in a million births.

        How many patients are there in the US?

        according to new release 8/9/12, ...Aegerion hasn’t revealed its pricing plan for lomitapide, but Beer says he expects it will fall in the range of $200,000 to $400,000 per patient per year. The consensus among the analysts covering the company is that Aegerion will bring in $26.5 million in sales next year (2013)...

        drug itself is dirty cheap to make...patients outside of US will not be paying anything close to $200,000 per patient per year (maybe $2000 in India/China and other countries the drug prices are much lower or out of IP protected areas; plus through oversea mailing order)

        Good luck

        Sentiment: Strong Sell

 
AEGR
19.83-0.33(-1.64%)1:58 PMEDT